Fax: +39-6-91093-482
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Tumor Immunology
You have full text access to this OnlineOpen article
Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA
Article first published online: 19 MAY 2005
DOI: 10.1002/ijc.21188
Copyright © 2005 Wiley-Liss, Inc.
Additional Information
How to Cite
Mennuni, C., Calvaruso, F., Facciabene, A., Aurisicchio, L., Storto, M., Scarselli, E., Ciliberto, G. and La Monica, N. (2005), Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer, 117: 444–455. doi: 10.1002/ijc.21188
Publication History
- Issue published online: 14 SEP 2005
- Article first published online: 19 MAY 2005
- Manuscript Accepted: 7 MAR 2005
- Manuscript Received: 3 NOV 2004
Funded by
- Italian MIUR. Grant Number: FIRB RBME017BC4
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , Genetic cancer vaccines: current status and perspectives, Expert Opinion on Biological Therapy, 2012, 1
- 2, , , , , , , , , , Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models, Vaccine, 2012, 30, 12, 2187
- 3, , , , , , , , , , A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine, Vaccine, 2010, 28, 20, 3522
- 4, , , , , , , , , , , , , , , , , HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy, Journal of Immunotherapy, 2010, 33, 4, 402
- 5, , , , , Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs, Vaccine, 2010, 28, 5, 1201
- 6, , , , , , , , , , A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines, Vaccine, 2009, 27, 9, 1293
- 7, , , , , , , A Novel Mouse Model for Evaluation and Prediction of HLA-A2-restricted CEA Cancer Vaccine Responses, Journal of Immunotherapy, 2009, 32, 7, 744
- 8, , , , , , , , , A Therapeutic Cancer Vaccine Targeting Carcinoembryonic Antigen in Intestinal Carcinomas, Human Gene Therapy, 2009, 20, 2, 125
- 9, , , , , , Antiapoptotic Small Interfering RNA as Potent Adjuvant of DNA Vaccination in a Mouse Mammary Tumor Model, Human Gene Therapy, 2009, 20, 6, 589
- 10, , , , , , , , , , , , , Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates, Molecular Therapy, 2009, 17, 10, 1804
- 11, , , , , , , , , , , , ErbB2 Genetic Cancer Vaccine in Nonhuman Primates: Relevance of Single Nucleotide Polymorphisms, Human Gene Therapy, 2009, 20, 3, 253
- 12, , , , , , An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models, Cancer Gene Therapy, 2008, 16, 5, 462
- 13, , , , , , , , , Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells, Vaccine, 2008, 26, 4, 509
- 14, , , , , , , , , , , , , Therapeutic Vaccination Halts Disease Progression in BALB-neuT Mice: The Amplitude of Elicited Immune Response Is Predictive of Vaccine Efficacy, Human Gene Therapy, 2008, 19, 7, 670
- 15, , , , , , , Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice, International Journal of Cancer, 2007, 120, 3Direct Link:
- 16, , , Adenovirus-based Prime-boost Immunization for Rapid Vaccination Against Anthrax, Molecular Therapy, 2007, 15, 1, 203
- 17, Enhanced immune responses to an adenovirus CEA vaccine in CD4+CD25+regulatory T-cell inactivated mice, Expert Review of Vaccines, 2007, 6, 1, 21
- 18, , , , Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease, Immunology Letters, 2007, 112, 1, 30
- 19, , , , , , , , , , Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates, International Journal of Cancer, 2007, 120, 11Direct Link:
- 20, , , , , , , , , , Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice, International Journal of Cancer, 2007, 120, 3Direct Link:
- 21, , , , , , , CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge, Cancer Gene Therapy, 2006, 14, 2, 201
- 22, , , , , , , , CD8+ T-Cell Tolerance can be Broken by an Adenoviral Vaccine While CD4+ T-Cell Tolerance is Broken by Additional Co-administration of a Toll-Like Receptor Ligand, Scandinavian Journal of Immunology, 2006, 63, 1Direct Link:
- 23, , , , , , , DNA and Adenoviral Vectors Encoding Carcinoembryonic Antigen Fused to Immunoenhancing Sequences Augment Antigen-Specific Immune Response and Confer Tumor Protection, Human Gene Therapy, 2006, 17, 1, 81
- 24, , , , , , , , , , , Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: Initial identification of predictive biomarkers, European Journal of Immunology, 2006, 36, 5Direct Link:
- 25, , , , Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines, Journal of Immunological Methods, 2006, 316, 1-2, 84
- 26, , , , , , , DNA and Adenoviral Vectors Encoding Carcinoembryonic Antigen Fused to Immunoenhancing Sequences Augment Antigen-Specific Immune Response and Confer Tumor Protection, Human Gene Therapy, 2005, 0, 0, 051221055625001